Otsuka receives FDA priority review for ADHD drug centanafadine
Tweet Send to a Friend
The U.S. Food and Drug Administration has accepted Otsuka Pharmaceutical's new drug application for centanafadine and granted it priority review ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


